• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

DAUNORUBICIN Drug Record

  • Summary
  • Interactions
  • Claims
  • DAUNORUBICIN chembl:CHEMBL178 ApprovedAntineoplasticImmunotherapy

    Alternate Names:

    FI-6339
    NSC-83142
    DAUNORUBICIN
    RP-13057
    RP 13057
    DAUNOXOME
    CERUBIDINE
    VALRUBICIN IMPURITY, DAUNORUBICIN
    FI 6339
    LEUKAEMOMYCIN C
    (8S-CIS)-8-ACETYL-10-((3-AMINO-2,3,6-TRIDEOXY-ALPHA-L-LYXO-HEXOPYRANNOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPTHACENEDIONE
    RUBIDOMYCIN
    NDC-0082-4155
    ACETYLADRIAMYCIN
    (+)-DAUNOMYCIN
    DAUNOMYCIN
    CERUBIDINE®
    DAUNORUBICINA
    DAUNORUBICINUM
    DAUNORUBICINE
    drugbank:00694
    pubchem.compound:30323
    rxcui:3109
    chemidplus:20830-81-3
    chembl:CHEMBL178

    Drug Info:

    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antineoplastic agent
    (6 More Sources)

    Publications:

    Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
    López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
    Caldwell et al., 2013, Overexpression of GATA1 confers resistance to chemotherapy in acute megakaryocytic Leukemia., PLoS ONE
    Aubel-Sadron et al., 1984, Daunorubicin and doxorubicin, anthracycline antibiotics, a physicochemical and biological review., Biochimie
    Zunino et al., 1990, DNA topoisomerase II as the primary target of anti-tumor anthracyclines., Anticancer Drug Des.
    McPherson et al., Selective sensitization of adriamycin-resistant P388 murine leukemia cells to antineoplastic agents following transfection with human DNA topoisomerase II alpha., Anticancer Res.
    Bains OS et al., 2010, Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin., J Pharmacol Exp Ther
    Thompson P et al., 2014, Pharmacokinetics and pharmacogenomics of daunorubicin in children: a report from the Children's Oncology Group., Cancer Chemother Pharmacol
    Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
    Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res
    FitzGerald et al., 1987, Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine., Anticancer Drug Des.
    Karol SE et al., 2016, Genetic risk factors for the development of osteonecrosis in children under age 10 treated for acute lymphoblastic leukemia., Blood
    He H et al., 2014, Association of nitric oxide synthase 3 (NOS3) 894 G>T polymorphism with prognostic outcomes of anthracycline in Chinese patients with acute myeloid leukaemia., Clin Exp Pharmacol Physiol
    Bains OS et al., 2010, Naturally occurring variants of human CBR3 alter anthracycline in vitro metabolism., J Pharmacol Exp Ther
    Bagrintseva et al., 2005, FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)., Blood
    Stone et al., 2017, Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation., N. Engl. J. Med.
    Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.
    Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
    Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem
    Bains OS et al., 2009, Two nonsynonymous single nucleotide polymorphisms of human carbonyl reductase 1 demonstrate reduced in vitro metabolism of daunorubicin and doxorubicin., Drug Metab Dispos
    Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.
    Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
    Elgie et al., 1999, Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML., Adv. Exp. Med. Biol.
    He H et al., 2015, Association of ABCB1 polymorphisms with prognostic outcomes of anthracycline and cytarabine in Chinese patients with acute myeloid leukemia., Eur J Clin Pharmacol
    Megías-Vericat JE et al., 2015, Influence of ABCB1 polymorphisms upon the effectiveness of standard treatment for acute myeloid leukemia: a systematic review and meta-analysis of observational studies., Pharmacogenomics J
    Gréen H et al., 2012, Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype., Pharmacogenomics J
    Kim DH et al., 2006, Multidrug resistance-1 gene polymorphisms associated with treatment outcomes in de novo acute myeloid leukemia., Int J Cancer
    Durdux et al., Fluorescence-based assessment of LRP activity: a comparative study., Anticancer Res.
    Wesselborg et al., 1999, Anticancer drugs induce caspase-8/FLICE activation and apoptosis in the absence of CD95 receptor/ligand interaction., Blood
    Huang RS et al., 2008, Genetic variants contributing to daunorubicin-induced cytotoxicity., Cancer Res
    Stacy AE et al., 2013, Molecular pharmacology of ABCG2 and its role in chemoresistance., Mol Pharmacol
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Bour-Dill et al., 2000, Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis., Cytometry
    Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
    Howlett et al., 1999, Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation., Biochem. J.
    Amitai Y et al., 1996, Glucose-6-phosphate dehydrogenase deficiency severely restricts the biotransformation of daunorubicin in human erythrocytes., J Lab Clin Med
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol
  • DAUNORUBICIN   NRP2

    Interaction Score: 1.93

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18451141


    Sources:
    PharmGKB

  • DAUNORUBICIN   AKR7A2

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20837989


    Sources:
    PharmGKB

  • DAUNORUBICIN   SETD4

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19204081


    Sources:
    PharmGKB

  • DAUNORUBICIN   AKR1C4

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20837989


    Sources:
    PharmGKB

  • DAUNORUBICIN   GATA1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type megakaryocytic leukemia
    Response Type decreased response
    Approval Status Preclinical - Cell culture

    PMIDs:
    23874683


    Sources:
    JAX-CKB

  • DAUNORUBICIN   RPSA

    Interaction Score: 0.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15161018


    Sources:
    NCI

  • DAUNORUBICIN   ATP7B

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25119182


    Sources:
    PharmGKB

  • DAUNORUBICIN   CBR1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19204081


    Sources:
    PharmGKB

  • DAUNORUBICIN   CBR3

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20007405


    Sources:
    PharmGKB

  • DAUNORUBICIN   IKZF1

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30044693


    Sources:
    CIViC

  • DAUNORUBICIN   PNPLA3

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28744905


    Sources:
    PharmGKB

  • DAUNORUBICIN   WT1

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18591546


    Sources:
    CIViC

  • DAUNORUBICIN   DROSHA

    Interaction Score: 0.28

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24614921


    Sources:
    PharmGKB

  • DAUNORUBICIN   FMO3

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25119182


    Sources:
    PharmGKB

  • DAUNORUBICIN   BMP7

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DAUNORUBICIN   LINC00251

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DAUNORUBICIN   AKR1C3

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20837989


    Sources:
    PharmGKB

  • DAUNORUBICIN   DOK5

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26590194


    Sources:
    PharmGKB

  • DAUNORUBICIN   DCK

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25119182


    Sources:
    PharmGKB

  • DAUNORUBICIN   SLC28A3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAUNORUBICIN   GATA3

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • DAUNORUBICIN   FAS

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10216102


    Sources:
    NCI

  • DAUNORUBICIN   CYP1A1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15588138


    Sources:
    NCI

  • DAUNORUBICIN   NOS3

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24684492


    Sources:
    PharmGKB

  • DAUNORUBICIN   TOP2A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Novel drug target Established target
    Trial Name CPX-351, cytarabine + daunorubicin

    PMIDs:
    6380596 1963303 9494516 22260166


    Sources:
    DTC TdgClinicalTrial NCI

  • DAUNORUBICIN   FLT3

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cytarabine + Daunorubicin + Midostaurin
    Indication/Tumor Type acute myeloid leukemia
    Response Type sensitive

    PMIDs:
    15626738 28644114 25818407 22627678


    Sources:
    JAX-CKB NCI CIViC

  • DAUNORUBICIN   TYMS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2967076


    Sources:
    NCI PharmGKB

  • DAUNORUBICIN   TYMSOS

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAUNORUBICIN   UGT1A6

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAUNORUBICIN   TOP2B

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name CPX-351, cytarabine + daunorubicin
    Novel drug target Established target

    PMIDs:
    6380596 1963303


    Sources:
    TdgClinicalTrial

  • DAUNORUBICIN   HDAC11

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   APP

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10510309


    Sources:
    NCI

  • DAUNORUBICIN   RARG

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • DAUNORUBICIN   HDAC9

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC10

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC7

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC8

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC3

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC2

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC6

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   HDAC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22260166


    Sources:
    DTC

  • DAUNORUBICIN   GSTP1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25119182


    Sources:
    PharmGKB

  • DAUNORUBICIN   ABCC1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10655559


    Sources:
    NCI

  • DAUNORUBICIN   SLCO1B1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26663398


    Sources:
    PharmGKB

  • DAUNORUBICIN   ABCG2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24021215


    Sources:
    PharmGKB

  • DAUNORUBICIN   CBFB

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   ABCB1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10500777 25567217 25558979 20938465 16331627


    Sources:
    NCI PharmGKB

  • DAUNORUBICIN   RUNX1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   G6PD

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    8648264


    Sources:
    PharmGKB

  • DAUNORUBICIN   TOP1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21094049


    Sources:
    DTC

  • DAUNORUBICIN   THRB

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   BLM

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   RECQL

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   APEX1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    16243804


    Sources:
    JAX-CKB

  • DAUNORUBICIN   HTT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   USP1

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   POLK

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   KDM4E

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   MAPT

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DAUNORUBICIN   EHMT2

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • TdgClinicalTrial: DAUNORUBICIN

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • NCI: DAUNORUBICIN

    • Version: 14-September-2017

    Alternate Names:
    C1583 NCI drug code

    Drug Info:

    Publications:
    Schröterová et al., 2004, The effect of new lipophilic chelators on the activities of cytosolic reductases and P450 cytochromes involved in the metabolism of anthracycline antibiotics: studies in vitro., Physiol Res
    Elgie et al., 1999, Comparison of P-glycoprotein expression and function with in vitro sensitivity to anthracyclines in AML., Adv. Exp. Med. Biol.
    Bour-Dill et al., 2000, Determination of intracellular organelles implicated in daunorubicin cytoplasmic sequestration in multidrug-resistant MCF-7 cells using fluorescence microscopy image analysis., Cytometry

  • NCI: DAUNOMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C1583 NCI drug code

    Drug Info:

    Publications:
    FitzGerald et al., 1987, Inhibition of thymidylate synthase in intact L1210 cells by ara-C, daunomycin, hydroxyurea and 3,4-dihydroxybenzylamine., Anticancer Drug Des.
    Howlett et al., 1999, Common structural features determine the effectiveness of carvedilol, daunomycin and rolitetracycline as inhibitors of Alzheimer beta-amyloid fibril formation., Biochem. J.

  • DTC: DAUNORUBICIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL178 ChEMBL Drug ID

    Drug Info:

    Publications:
    Guerrant W et al., 2012, Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors., J Med Chem
    Shi W et al., 2011, Cytotoxicity and topoisomerase I/II inhibition of glycosylated 2-phenyl-indoles, 2-phenyl-benzo[b]thiophenes and 2-phenyl-benzo[b]furans., Bioorg Med Chem

  • JAX-CKB: Daunorubicin

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.
    Stone et al., 2012, Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia., Leukemia
    Fiedler et al., 2015, A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations., Br. J. Haematol.

  • JAX-CKB: Daunoxome

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Xu et al., 2005, p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer., Clin. Cancer Res.

  • PharmGKB: daunorubicin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    López-López E et al., 2014, Pharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemia., PLoS One
    Drenberg CD et al., 2016, Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia., Clin Pharmacol Ther
    Huang RS et al., 2008, Genetic variants contributing to daunorubicin-induced cytotoxicity., Cancer Res

  • CIViC: DAUNORUBICIN

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Bagrintseva et al., 2005, FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L)., Blood
    Virappane et al., 2008, Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party., J. Clin. Oncol.
    Yeoh AEJ et al., 2018, Intensifying Treatment of Childhood B-Lymphoblastic Leukemia With IKZF1 Deletion Reduces Relapse and Improves Overall Survival: Results of Malaysia-Singapore ALL 2010 Study., J Clin Oncol

  • TTD: Daunorubicin

    • Version: 2020.06.01

    Alternate Names:
    D01XWG TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL178

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21